Literature DB >> 32534202

Janus kinases inhibitors for treating patients with rhupus.

Cristina Garufi1, Silvia Mancuso1, Francesca Romana Spinelli2, Simona Truglia1, Fulvia Ceccarelli1, Cristiano Alessandri1, Fabrizio Conti1.   

Abstract

Entities:  

Keywords:  Baricitinib; JAK-inhibitors; Lupus nephritis; Rheumatoid Arthritis; Rhupus; Systemic Lupus Erythematosus; Tofacitinib

Mesh：

Substances：

Year:  2020        PMID： 32534202     DOI： 10.1016/j.jbspin.2020.05.010

Source DB:  PubMed          Journal:  Joint Bone Spine        ISSN： 1297-319X            Impact factor:   4.929


× No keyword cloud information.
  2 in total

1.  Complete remission of tip lesion variant focal segmental glomerulosclerosis (FSGS) with the Janus Kinase (JAK) inhibitor tofacitinib.

Authors:  Martin Sedlacek; Jason R Pettus
Journal:  CEN Case Rep       Date:  2021-11-05

Review 2.  Why Do We Need JAK Inhibitors in Systemic Lupus Erythematosus?

Authors:  Patricia Richter; Anca Cardoneanu; Alexandra Maria Burlui; Luana Andreea Macovei; Ioana Bratoiu; Oana Nicoleta Buliga-Finis; Elena Rezus
Journal:  Int J Mol Sci       Date:  2022-10-04       Impact factor: 6.208
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.